Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: SDZNY )

44.74 -0.25 (-0.56%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about SDZNY

Sandoz receives European Commission approval for Afqlir® (aflibercept), further strengthening leading biosimilar portfolio
From Sandoz Group
Via GlobeNewswire
Sandoz reports third-quarter and nine-month 2024 sales
From Sandoz Group
Via GlobeNewswire
Sandoz US launches generic paclitaxel in single-dose vial, further expanding US oncology portfolio
From Sandoz Group
Via GlobeNewswire
Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further strengthening US biosimilar position
From Sandoz Group
Via GlobeNewswire
Sandoz reports second-quarter sales and half-year 2024 results
From Sandoz Group
Via GlobeNewswire
Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat chronic inflammatory diseases
From Sandoz Group
Via GlobeNewswire
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024 
Via MarketBeat
FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized by Sandoz in US
From Sandoz Group
Via GlobeNewswire
Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilars of denosumab in Europe
From Sandoz Group
Via GlobeNewswire
Sandoz reports first quarter 2024 sales
From Sandoz Group
Via GlobeNewswire
Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
From Sandoz Group
Via GlobeNewswire
Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
From Sandoz Group
Via GlobeNewswire
Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
From Sandoz Group
Via GlobeNewswire
Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
From Sandoz Group
Via GlobeNewswire
Sandoz reports fourth quarter 2023 sales and full-year 2023 results
From Sandoz Group
Via GlobeNewswire
Sandoz receives FDA approval for first and only denosumab biosimilars
From Sandoz Group
Via GlobeNewswire
Sandoz announces nominations to the Board of Directors and leadership change
From Sandoz Group
Via GlobeNewswire
Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
From Sandoz Group
Via GlobeNewswire
Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
From Sandoz Group
Via GlobeNewswire
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities. 
Via MarketBeat
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.